title: Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study.
abstract: 362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 mg/m2), and fluorouracil (500 mg/m2; CNF). After a median follow-up of 51 months, 64 (36%) patients relapsed in the CMF group and 60 (33%) in the CNF group (p=0.8276). By Cox multivariate analysis, tumor size, menopausal status and number of involved nodes were retained as independently significant variables. Toxicities were remarkably similar in both groups. It appears that after a median follow-up of 51 months there is no significant difference in relapse-free survival between node-positive patients with breast cancer who received either 6 cycles of the conventional CMF or the CNF combination as adjuvant treatment.
authors.affiliation: 1st Department of Internal Medicine, Oncology Section, AHEPA Hospital, Aristotle University, Thessaloniki, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Fountzilas
authors.forename: A
authors.initials: A
authors.lastname: Polichronis
authors.forename: K
authors.initials: K
authors.lastname: Katsohis
authors.forename: K
authors.initials: K
authors.lastname: Gennatas
authors.forename: D
authors.initials: D
authors.lastname: Toussis
authors.forename: D
authors.initials: D
authors.lastname: Skarlos
authors.forename: P
authors.initials: P
authors.lastname: Kosmidis
authors.forename: S
authors.initials: S
authors.lastname: Vassilaros
authors.forename: C
authors.initials: C
authors.lastname: Semoglou
authors.forename: T
authors.initials: T
authors.lastname: Giannakakis
authors.forename: E
authors.initials: E
authors.lastname: Fahantidis
authors.forename: G
authors.initials: G
authors.lastname: Klouvas
authors.forename: N
authors.initials: N
authors.lastname: Tsavaris
authors.forename: C
authors.initials: C
authors.lastname: Konstantaras
authors.forename: P
authors.initials: P
authors.lastname: Makrantonakis
authors.forename: C
authors.initials: C
authors.lastname: Kolotas
authors.forename: N
authors.initials: N
authors.lastname: Zamboglou
authors.forename: S
authors.initials: S
authors.lastname: Tsiliakos
authors.forename: D
authors.initials: D
authors.lastname: Hainoglou
authors.forename: N
authors.initials: N
authors.lastname: Mylonakis
authors.forename: N
authors.initials: N
authors.lastname: Pavlidis
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D003520:Cyclophosphamide; D008942:Mitoxantrone; D005472:Fluorouracil; D008727:Methotrexate